Multiplex ligation-dependent probe amplification can clarify HER2 status in gastric cancers with "polysomy 17"

Journal of Cancer

Volumn 6, Issue 5, 2015, Pages 403-408

  Wang, Tao ^a   Amemiya, Yutaka ^b   Henry, Pauline ^a,c   Seth, Arun ^a,b,d   Hanna, Wedad ^a,d   Hsieh, Eugene T ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canada   (Canada)

^c TORONTO EAST GENERAL HOSPITAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Gastric cancer; HER2; In situ hybridization; Multiplex ligation dependent probe amplification; Polysomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CENTROMERE; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME DUPLICATION; CONTROLLED STUDY; GENE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYSOMY 17; STOMACH CANCER; WSB1 GENE;

EID: 84930196880     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11424     Document Type: Article

References (20)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (To-GA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97.
2. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.
3. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25: 637-50.
4. Chung H, Bang YJ, Xu JM, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. Eur J Cancer Suppl. 2009; 7: 364.
5. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat. 2010; 120: 1-7.
6. Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol. 2011; 29: 4168-74.
7. Moelans CB, de Weger RA, Ezendam C, van Diest PJ. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification: influence of manual-and laser microdissection. BMC Cancer. 2009; 9: 4.
8. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010; 23: 1029-39.
9. Moelans CB, de Weger RA, van Blokland MTM, van der Wall E, van Diest PJ. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol. 2010; 23: 62-70.
10. Hsieh E, Henry P, Kwok K, Hanna W. HER2/Neu testing in 207 gastric and gastroesophageal junction adenocarcinomas: immunohistochemistry and silver in situ hybridization (SISH) provide effective brightfield methods for clinical HER2 testing. Modern Pathology. 2012; 25 (Suppl 2): 163A.
11. Dentice M, Bandyopadhyay A, Gereben B, et al. The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol. 2005; 7: 698-705.
12. Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ, Xia Q. HIF1 regulates WSB-1 expression to promote hypoxia-induced chemoresistance in hepatocellular carcinoma cells. FEBS Lett. 2013; 587: 2530-5.
13. Rossi E, Klersy C, Manca R, Zuffardi O, Solcia E. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Human Pathol. 2011; 42: 1937-45.
14. Yang S, Jeung HC, Jeong HJ, Choi YH, Kim JE, Jung JJ, Rha SY, Yang WI, Chung HC. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics. 2007; 89: 451-9.
15. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIa gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Human Pathol. 2006; 37: 1333-43.
16. Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008; 8: 363.
17. Chan SH, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008; 28: 907-11.
18. Yang S, Huang C, Li X, Yu M, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicol. 2013; 306: 162-8.
19. Saito M, Kato Y, Ito E, et al. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett. 2012; 586: 1708-14.
20. Wolff A, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncoloty/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31: 3997-4013.